Fate Therapeutics

Fate Therapeutics showcased its master cell bank platform at the Cantor conference, which the company says could enable more than 10 million doses and reduce production costs to about $3,000 per dose. The lead program is FT819 for lupus nephritis; early data show pronounced UPCR reductions and management reports alignments with the FDA for a registration‑enabling phase II study. FT839 (CD19/CD38) received IND clearance and first patient treatment is expected in a few months. The company emphasizes a favorable safety profile in nearly 100 treated patients but sees execution risks from long timelines and competition. » Mais em de.investing.com

Fate Therapeutics presented preliminary clinical data on its allogeneic CAR‑T candidate FT819 at the annual meeting of the International Society for Stem Cell Research, focusing on the systemic sclerosis arm of the ongoing phase‑1 basket study. All of the first four patients treated between June 4 and 12 achieved a CRISS ≥25 at three months and showed improvements in the modified Rodnan skin score, with no reports of cytokine release syndrome, ICANS, GvHD, hypogammaglobulinemia, or deaths. FT819 is also being investigated in systemic lupus and is planned for a phase‑2 study in lupus nephritis. Fate Therapeutics is trading near its 52‑week high, has a market capitalization of about $340 million, and remained financially flexible despite cash burn of roughly $108 million. » Mais em de.investing.com

Fate Therapeutics will present data on three CAR‑T candidates at specialist conferences in late May/early June: preliminary Phase‑1 results for FT836 at the ASCO meeting, safety/efficacy data for FT819 and an oral presentation on FT839 at the European Congress of Rheumatology. The company is developing iPSC‑derived, “off‑the‑shelf” cellular immunotherapies. Investors should note that Fate is burning cash quickly, remains unprofitable, but the stock has risen sharply since the start of the year. » Mais em de.investing.com